IBDEI0XC ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16210,2)
 ;;=^21917
 ;;^UTILITY(U,$J,358.3,16211,0)
 ;;=607.84^^81^955^53
 ;;^UTILITY(U,$J,358.3,16211,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16211,1,4,0)
 ;;=4^607.84
 ;;^UTILITY(U,$J,358.3,16211,1,5,0)
 ;;=5^Male Erectile Disorder
 ;;^UTILITY(U,$J,358.3,16211,2)
 ;;=^270441
 ;;^UTILITY(U,$J,358.3,16212,0)
 ;;=173.99^^81^955^83
 ;;^UTILITY(U,$J,358.3,16212,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16212,1,4,0)
 ;;=4^173.99
 ;;^UTILITY(U,$J,358.3,16212,1,5,0)
 ;;=5^Skin Cancer NOS
 ;;^UTILITY(U,$J,358.3,16212,2)
 ;;=^340493
 ;;^UTILITY(U,$J,358.3,16213,0)
 ;;=278.01^^81^955^55
 ;;^UTILITY(U,$J,358.3,16213,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16213,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,16213,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,16213,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,16214,0)
 ;;=585.6^^81^955^34
 ;;^UTILITY(U,$J,358.3,16214,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16214,1,4,0)
 ;;=4^585.6
 ;;^UTILITY(U,$J,358.3,16214,1,5,0)
 ;;=5^End Stage Renal Disease
 ;;^UTILITY(U,$J,358.3,16214,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,16215,0)
 ;;=482.1^^81^955^81
 ;;^UTILITY(U,$J,358.3,16215,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16215,1,4,0)
 ;;=4^482.1
 ;;^UTILITY(U,$J,358.3,16215,1,5,0)
 ;;=5^Pseudomonal Pneumonia
 ;;^UTILITY(U,$J,358.3,16215,2)
 ;;=^269932
 ;;^UTILITY(U,$J,358.3,16216,0)
 ;;=482.2^^81^955^37
 ;;^UTILITY(U,$J,358.3,16216,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16216,1,4,0)
 ;;=4^482.2
 ;;^UTILITY(U,$J,358.3,16216,1,5,0)
 ;;=5^H. Influenzae Pneumonia
 ;;^UTILITY(U,$J,358.3,16216,2)
 ;;=^269933
 ;;^UTILITY(U,$J,358.3,16217,0)
 ;;=482.84^^81^955^50
 ;;^UTILITY(U,$J,358.3,16217,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16217,1,4,0)
 ;;=4^482.84
 ;;^UTILITY(U,$J,358.3,16217,1,5,0)
 ;;=5^Legionnaires' Disease
 ;;^UTILITY(U,$J,358.3,16217,2)
 ;;=^68817
 ;;^UTILITY(U,$J,358.3,16218,0)
 ;;=482.9^^81^955^17
 ;;^UTILITY(U,$J,358.3,16218,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16218,1,4,0)
 ;;=4^482.9
 ;;^UTILITY(U,$J,358.3,16218,1,5,0)
 ;;=5^Bacterial Pneumonia NOS
 ;;^UTILITY(U,$J,358.3,16218,2)
 ;;=^12347
 ;;^UTILITY(U,$J,358.3,16219,0)
 ;;=430.^^81^955^88
 ;;^UTILITY(U,$J,358.3,16219,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16219,1,4,0)
 ;;=4^430.
 ;;^UTILITY(U,$J,358.3,16219,1,5,0)
 ;;=5^Subarachnoid Hemorrhage
 ;;^UTILITY(U,$J,358.3,16219,2)
 ;;=^114989
 ;;^UTILITY(U,$J,358.3,16220,0)
 ;;=434.91^^81^955^24
 ;;^UTILITY(U,$J,358.3,16220,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16220,1,4,0)
 ;;=4^434.91
 ;;^UTILITY(U,$J,358.3,16220,1,5,0)
 ;;=5^Crb Art Occl,Unspec w/ CRB Inf
 ;;^UTILITY(U,$J,358.3,16220,2)
 ;;=^295738
 ;;^UTILITY(U,$J,358.3,16221,0)
 ;;=431.^^81^955^47
 ;;^UTILITY(U,$J,358.3,16221,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16221,1,4,0)
 ;;=4^431.
 ;;^UTILITY(U,$J,358.3,16221,1,5,0)
 ;;=5^Intracerebral Hemorrhage
 ;;^UTILITY(U,$J,358.3,16221,2)
 ;;=^64977
 ;;^UTILITY(U,$J,358.3,16222,0)
 ;;=432.1^^81^955^89
 ;;^UTILITY(U,$J,358.3,16222,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16222,1,4,0)
 ;;=4^432.1
 ;;^UTILITY(U,$J,358.3,16222,1,5,0)
 ;;=5^Subdural Hemorrhage
 ;;^UTILITY(U,$J,358.3,16222,2)
 ;;=^115061
 ;;^UTILITY(U,$J,358.3,16223,0)
 ;;=784.3^^81^955^8
 ;;^UTILITY(U,$J,358.3,16223,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16223,1,4,0)
 ;;=4^784.3
 ;;^UTILITY(U,$J,358.3,16223,1,5,0)
 ;;=5^Aphasia
 ;;^UTILITY(U,$J,358.3,16223,2)
 ;;=^9453
 ;;^UTILITY(U,$J,358.3,16224,0)
 ;;=784.51^^81^955^30
 ;;^UTILITY(U,$J,358.3,16224,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16224,1,4,0)
 ;;=4^784.51
 ;;
 ;;$END ROU IBDEI0XC
